annual cash & cash equivalents:
$594.35M+$202.78M(+51.79%)Summary
- As of today (June 19, 2025), RXRX annual cash & cash equivalents is $594.35 million, with the most recent change of +$202.78 million (+51.79%) on December 31, 2024.
- During the last 3 years, RXRX annual cash & cash equivalents has risen by +$309.23 million (+108.46%).
- RXRX annual cash & cash equivalents is now at all-time high.
Performance
RXRX Cash and cash equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly cash & cash equivalents:
$500.45M-$93.90M(-15.80%)Summary
- As of today (June 19, 2025), RXRX quarterly cash & cash equivalents is $500.45 million, with the most recent change of -$93.90 million (-15.80%) on March 31, 2025.
- Over the past year, RXRX quarterly cash & cash equivalents has increased by +$204.13 million (+68.89%).
- RXRX quarterly cash & cash equivalents is now -20.91% below its all-time high of $632.74 million, reached on June 30, 2021.
Performance
RXRX quarterly cash & cash equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Cash and cash equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
RXRX Cash and cash equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +51.8% | +68.9% |
| 3 y3 years | +108.5% | -1.5% |
| 5 y5 years | +750.5% | - |
RXRX Cash and cash equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | +108.5% | -15.8% | +68.9% |
| 5 y | 5-year | at high | +750.5% | -20.9% | +133.8% |
| alltime | all time | at high | +750.5% | -20.9% | +133.8% |
RXRX Cash and cash equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2025 | - | $500.45M(-15.8%) |
| Dec 2024 | $594.35M(+51.8%) | $594.35M(+39.0%) |
| Sep 2024 | - | $427.65M(-9.8%) |
| Jun 2024 | - | $474.34M(+60.1%) |
| Mar 2024 | - | $296.33M(-24.3%) |
| Dec 2023 | $391.56M(-28.8%) | $391.56M(+1.1%) |
| Sep 2023 | - | $387.32M(-4.6%) |
| Jun 2023 | - | $405.87M(-14.2%) |
| Mar 2023 | - | $473.14M(-14.0%) |
| Dec 2022 | $549.91M | $549.91M(+21.0%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2022 | - | $454.65M(+0.2%) |
| Jun 2022 | - | $453.88M(-10.6%) |
| Mar 2022 | - | $507.89M(+78.1%) |
| Dec 2021 | $285.12M(+8.8%) | $285.12M(-27.8%) |
| Sep 2021 | - | $394.72M(-37.6%) |
| Jun 2021 | - | $632.74M(+195.6%) |
| Mar 2021 | - | $214.09M(-18.3%) |
| Dec 2020 | $262.13M(+275.1%) | - |
| Dec 2020 | - | $262.13M |
| Dec 2019 | $69.88M | - |
FAQ
- What is Recursion Pharmaceuticals annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Recursion Pharmaceuticals?
- What is Recursion Pharmaceuticals annual cash & cash equivalents year-on-year change?
- What is Recursion Pharmaceuticals quarterly cash & cash equivalents?
- What is the all time high quarterly cash & cash equivalents for Recursion Pharmaceuticals?
- What is Recursion Pharmaceuticals quarterly cash & cash equivalents year-on-year change?
What is Recursion Pharmaceuticals annual cash & cash equivalents?
The current annual cash & cash equivalents of RXRX is $594.35M
What is the all time high annual cash & cash equivalents for Recursion Pharmaceuticals?
Recursion Pharmaceuticals all-time high annual cash & cash equivalents is $594.35M
What is Recursion Pharmaceuticals annual cash & cash equivalents year-on-year change?
Over the past year, RXRX annual cash & cash equivalents has changed by +$202.78M (+51.79%)
What is Recursion Pharmaceuticals quarterly cash & cash equivalents?
The current quarterly cash & cash equivalents of RXRX is $500.45M
What is the all time high quarterly cash & cash equivalents for Recursion Pharmaceuticals?
Recursion Pharmaceuticals all-time high quarterly cash & cash equivalents is $632.74M
What is Recursion Pharmaceuticals quarterly cash & cash equivalents year-on-year change?
Over the past year, RXRX quarterly cash & cash equivalents has changed by +$204.13M (+68.89%)